12 results about "Allotransplantation" patented technology

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) and / or mesenchymal stomal cells in other embodiments. Hydrogel carrier materials are also described herein.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) or allograft rejection in subjects receiving donor cells. Also disclosed are methods enhancing regulatory T (Treg) cells for use in preventing GVHD. Also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the treated Treg cells. Also disclosed are enhanced Treg cells produced by the disclosed methods that have been engineered to express chimeric antigen receptor (CAR) polypeptide cells.

The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

The present disclosure relates to methods of treating or reducing the risk of transplant rejection or increasing a duration of time before transplant rejection occurs in a subject in need thereof (e.g., a human) by administering an antagonist that targets CD40 or CD154, such as an anti-CD40 antibody or an antigen-binding fragment thereof (e.g., a humanized anti-CD40 antibody or antigen-binding fragment thereof. The transplant may be an allogeneic or xenogeneic transplant (e.g., a cell, tissue, or organ or portion thereof).

There is disclosed a system and methods for safely and securely gripping osseous-based tissue during allograft processing. One embodiment includes a first forceps half pivotally coupled to a second forceps half, where the first and the second forceps halves combine to form a handle portion and a head portion. The handle portion may define a first longitudinal axis, and the head portion may define a second longitudinal axis that intersects the first longitudinal axis at a varying head angle. The first and the second halves move between an open position in which the first and second forceps halves at the head portion are separated and a closed position in which the first and second forceps halves at the head portion are together. The forceps may also include an open-biasing spring element attached between the first and second forceps halves and a selective locking mechanism. Other embodiments are also disclosed.

There is disclosed a system and methods for safely and securely gripping osseous-based tissue during allograft processing. One embodiment includes a first forceps half pivotally coupled to a second forceps half, where the first and the second forceps halves combine to form a handle portion and a head portion. The handle portion may define a first longitudinal axis, and the head portion may define a second longitudinal axis that intersects the first longitudinal axis at a varying head angle. The first and the second halves move between an open position in which the first and second forceps halves at the head portion are separated and a closed position in which the first and second forceps halves at the head portion are together. The forceps may also include an open-biasing spring element attached between the first and second forceps halves and a selective locking mechanism. Other embodiments are also disclosed.

Provided are a composition and method for allogeneic transplantation. Provided is an sgRNA combination targeting HLA class I genes, which can knock out HLA-A and HLA-B with high efficiency, and knock out HLA-C with low efficiency. The sgRNA combination can be used for preparing engineered cells with modified HLA class I genes, and the obtained engineered cells can be further used in the prevention and / or treatment of diseases such as cancer, infection or autoimmune diseases.

The present invention relates to methods for monitoring potential indications of allogeneic organ rejection by monitoring transplanted hair follicles from the same donor of a transplanted organ, and for performing or modifying immunosuppressive therapy to ameliorate or prevent the occurrence of acute or chronic organ rejection. The methods of the invention may also be used to select candidate allogeneic solid organ donors for recipients, as well as to improve the occurrence of acute rejection of transplanted allogeneic solid organs, such as kidneys.

The present disclosure provides a gel composition comprising: a porous scaffold and a gel coating. The porous scaffold is filled with a biological tissue or a biological cell, and the gel coating covers the porous scaffold. The present disclosure further provides the manufacturing method and the use of the foregoing gel composition, especially the use as an implant for xenotransplantation or allotransplantation.